Viralytics Looks To Combos To Ride Immuno-Oncology Wave
This article was originally published in PharmAsia News
Australian oncology venture Viralytics is on something of a roll, announcing additional positive Phase II data for its lead drug Cavatak and progress with new plans to assess the oncolytic virus in combination with immune checkpoint inhibitors following promising early results.
You may also be interested in...
In Bristol’s CheckMate 067, PD-1 monotherapy performs as well as the PD-1/CTLA-4 combination in melanoma patients with higher expression of the PD-L1 biomarker, a finding that implies a personalized immunotherapy approach in the future.
Japanese major buys out existing cancer cell therapy research partner, exercising an exclusive option dating back to a 2017 collaboration and expanding its immuno-oncology ambitions and pipeline.
In this week's podcast edition of Five Must-Know Things: a slow start for Biogen’s Aduhelm; J&J looks to transition COVID vaccine to commercial sales; 2seventy bio spins out from bluebird bio; UCB faces bimekizumab delays; and progress and setbacks in gene therapy.